Transgenomic MX-ICP Panel for Lung Cancer
Transgenomic has launched a multiplexed ICE COLD PCR (MX-ICP) lung cancer panel with epidermal growth factor receptor (EGFR) analysis. The panel covers key actionable mutations while providing precision detection levels as low as 0.01 percent. Characteristic mutations in EGFR are found in many patients with lung tumors, and these mutations may be associated with susceptibility or resistance to certain targeted cancer drugs. The panel includes EGFR exons 18-21 to determine NSCLC tumor sensitivity or resistance to tyrosine kinase inhibitors. The MX-ICP technology in the panel generates highly accurate results from small amounts of blood or tissue samples and is available for diagnostic use through the company's CLIA laboratory, said Transgenomic in a statement.